Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DA-8010 in healthy subjects
NCT02821312Phase 1Unknown
- Sponsor
- Dong-A ST
- Start
- Jun 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of velufenacin in overactive bladder (OAB) (4 arms), sponsored by Dong-A ST. Primary endpoint: Safety and Tolerability. Status: unknown.
02
Drugs
velufenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02821312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821312.